Lidoderm Buyers, End Payors Win Cert. In Pay-For-Delay MDL

Law360, Los Angeles (February 21, 2017, 9:16 PM EST) -- Purchasers of the Lidoderm pain patch won class certification in an antitrust multidistrict litigation against Endo Pharmaceuticals and others on Tuesday when a California federal judge found that both direct purchasers and end-payors proved common injuries with alleged delays of a generic version of the drug.

The buyers and end-payors of Lidoderm in the suit say that they overpaid for the patch because of a "reverse payment" patent litigation settlement that led to inflated costs. Endo and other defendants had argued that the plaintiffs can't show classwide proof of injury or damages from the agreement.

U.S. District Judge William Orrick on...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!